Have you been diagnosed with Molecular Low-Risk Early-Stage Breast Cancer? If so, you may be able to take part in a research study using lower dose of tamoxifen, to evaluate if it is a better treatment than usual hormonal therapy in women with low-risk, early-stage breast cancer.

Are you an adult with an intellectual disability (ID/D) age 18 to 30 years? Would you and your adult care partner like to participate in a one-hour zoom interview together to answer questions that can help researchers learn about school and community experiences and technology use that helps people with ID/D transition to adulthood? Digitial gift card compensation provided to both participants.

Do you have lupus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM)? You may be eligible for a new CAR-T therapy conducted at University of North Carolina at Chapel Hill. Please reach out to learn more about this new innovative treatment.

Are you a woman with a history of breast cancer (Stage 0-III)? Do you identify as Black/African-American? Do you struggle with fear or worry that your cancer may return? If you are a breast cancer survivor that identifies as Black/African-American, you may be eligible to participate in the FoRtitude Interview Study. Compensation provided.

Do you have metastatic or incurable, recurrent head and neck cancer? If so, you may be able to participate in a research study to find out if a new investigational drug, in combination with pembrolizumab, can help people with advanced head and neck cancer.

Have you been diagnosed with Ovarian Cancer? Have you received cytoreductive surgery? If so, you may be able to take part in a study on a new ovarian cancer treatment. We want to find out if taking a medicine called Olaparib for one year works as well as the usual treatment for ovarian cancer. We also want to see if Olaparib can help stop the cancer from growing or coming back.

Have you been diagnosed with early stage triple negative breast cancer and not yet received treatment? If so, you may be eligible for a trial comparing the use two different regimens of chemotherapy-immunotherapy treatments prior to surgery.

Do you have solid tumor of the lung or esophagus? Have the standard treatments for your condition been ineffective or not tolerable? If so, you may be eligible to participate in an early phase research study of the investigational drug YL201 as a possible treatment for advanced solid tumors.

The aim of this study is to measure the efficacy (how well it works) and safety of efgartigimod compared with placebo (inactive substance) in participants with ocular myasthenia gravis (oMG). The study will also measure the long-term efficacy, safety, and tolerability of efgartigimod.

Have you been diagnosed with advanced breast, lung, colorectal, or bladder cancer and does your doctor plan to send a sample of your tumor for genetic testing? If so, then you may be able to take part in a research study that looks at whether an expert review of your tumor genetic test results can help your doctor identify better treatment options or clinical trials that may be suitable for your cancer.